Clinical Trial

Genistein, Equol, Cognitive Function and Mood: Acute. (GECFAMa)

Study acronym: GECFAMa
Completed
View on ClinicalTrials.gov →
Summary
Isoflavones (ISF) are naturally occurring compounds that can provide protective benefits for certain domains of cognitive function. Studies on the prevalence of cognitive decline and cancers in the Asian diet-eating areas of the world have investigated the effects of the ISFs and how they affect our bodies and brains. Previous literature has shown that ISFs are capable of binding oestrogen receptors in our brains that provide protection in terms of antioxidation, anti-inflammatory and promoting the growth and interaction of our brain cells. Genistein is an important ISF having been shown to provide a strong protective response in our brains and other aspects of healthcare; Equol is a metabolite of ISF and is thought to provide a similar (or stronger) response than Genistein due to its receptor binding strength. Unfortunately, not everyone is capable of digesting Equol from other Isoflavones (Daidzein) and therefore supplementing this directly could provide neurological benefits at a similar level, if not stronger than, Genistein. This acute study will aim to evaluate the efficacies of two ISFs (Genistein and Equol) versus a control group, in an immediately post-prandial timeframe. SIF are "Generally Recognised As Safe" ("GRAS") molecules by the United States of America's classification regulatory commission the Federal Drug Administration as well as deemed "Safe" by the European Food Safety Authority (EFSA). Participant will be required to undertake 2 one hour-long sessions. Interventions will be taken once after the baseline task battery is completed.
Trial Details
NCT Number NCT07742514
Lead Sponsor University of Reading
Conditions Cognition, Mood
Enrollment 53 participants
Start Date 2024-11-14
Primary Completion 2025-10-14 (estimated)
Study Completion 2025-10-14 (estimated)
Updated on ClinicalTrials.gov 2026-08-07